Millennium Management’s Iovance Biotherapeutics IOVA Stock Holding History

Millennium Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-165,000	Closed	-$450K	–	6027
2025 Q4	$450K	Buy	+165,000	New	+$382K	﹤0.01%	5019
2023 Q4	–	Sell	-103,700	Closed	-$472K	–	6292
2023 Q3	$472K	Buy	+103,700	New	+$677K	﹤0.01%	4701
2022 Q3	–	Sell	-303,100	Closed	-$3.35M	–	7263
2022 Q2	$3.35M	Buy	+303,100	New	+$3.97M	﹤0.01%	3198
2021 Q2	–	Sell	-10,000	Closed	-$317K	–	6773
2021 Q1	$317K	Buy	+10,000	New	+$415K	﹤0.01%	5173
2020 Q2	–	Sell	-10,000	Closed	-$299K	–	4370
2020 Q1	$299K	Buy	+10,000	New	+$265K	﹤0.01%	3178

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management's IOVA Position: Q1 2026 in Review

Millennium Management increased its Iovance Biotherapeutics (IOVA) stake by 43% in Q1 2026, buying an estimated $9.05M and bringing the position to 9,414,292 shares worth $33M. The position accounts for 0.01% of the portfolio, ranked #1147.

Millennium Management first reported a position in IOVA in Q1 2015 and has held it in 38 quarters since. The position peaked at $39.5M in Q1 2022. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Millennium Management held 9,414,292 shares of Iovance Biotherapeutics worth $33M as of Q1 2026.
Millennium Management bought 2,828,760 Iovance Biotherapeutics shares in Q1 2026, an estimated $9.05M.
Iovance Biotherapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1147 holding.
Millennium Management first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 38 quarters since.
Millennium Management's Iovance Biotherapeutics position peaked at $39.5M in Q1 2022.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.